Fierce Pharma October 11, 2024
A little over four years after being sued by the United States, Teva is putting longstanding allegations that it paid kickbacks on a popular multiple sclerosis drug to bed.
Teva Pharmaceuticals USA and Teva Neuroscience have agreed to pay a combined $450 million to resolve claims that the company violated the country’s Anti-Kickback Statute (AKS) and the False Claims Act (FCA), the U.S. Department of Justice said Thursday.
The first $425-million tranche of the settlement covers claims that Teva leveraged two assistance foundations to fund patients’ copays for the blockbuster multiple sclerosis (MS) drug Copaxone from 2006 through 2017. During that period, the Justice Department contends Teva “steadily” raised Copaxone’s price.
Meanwhile, Teva will shell out another $25 million to...
Today's Sponsors
Today's Sponsor